U.S. markets closed

Aptose Biosciences Inc. (APTO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.7300+0.0631 (+9.46%)
At close: 04:00PM EST
0.7000 -0.03 (-4.11%)
After hours: 07:30PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected


Previous Close0.6669
Bid0.6595 x 2200
Ask0.7300 x 1000
Day's Range0.6520 - 0.7300
52 Week Range0.4500 - 2.1600
Avg. Volume361,436
Market Cap67.375M
Beta (5Y Monthly)1.32
PE Ratio (TTM)N/A
EPS (TTM)-0.6740
Earnings DateNov 01, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for APTO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Aptose Biosciences, Inc.
    Daily Spotlight: Important Inflation News Out TodayThe Federal Reserve's favorite inflation indicator, the PCE Price Index, will be released by the BEA today. The PCE Index differs from the better-known Consumer Price Index in that its components are more variable and are quicker to reflect real-time pricing fluctuations. In the most-recent report (from September), PCE inflation was reported at 6.2% (the latest CPI report, from October, had inflation at 7.7%). At Argus, we forecast a rate of 5.9% for the October PCE Price Index. Core PCE, which removes volatile food and energy prices, was 5.1% in the last month. We expect the Core PCE to tick lower to 5.0% this month. Overall, inflation appears to have peaked during the summer and is starting to decline. We track 21 inflation measures on a monthly basis. On average, they are indicating that prices are rising at a 5.2% rate year-over-year, down from 6.8% last month and from 8.7% four months ago. Drilling down to core inflation (which we obtain by averaging Core CPI, market-based PCE Ex-Food & Energy, the core GDP PCE Price Index, the five-year forward inflation expectation rate, and the 10-year TIPs Break-even Interest Rate), our reading is 4.1%. That's down slightly from our 4.3% reading last month. We note some movement among our components. Producer Prices appear to be cooling off, with substantial declines in PPI Intermediate Prices for Processed and Unprocessed Goods. The rate of wage increases also is slowing. Looking down the road, investors are expecting that the Federal Reserve's series of rate hikes ultimately will tame inflation, with the three-year forward expectation rate now down to 3.1% and the five-year forward expectation rate at 2.3%.
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • GlobeNewswire

    Aptose Treats First Patient with Continuous Dosing of New “G3” Formulation of Luxeptinib

    SAN DIEGO and TORONTO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced dosing of the first patient to receive a continuous dosing regimen of the G3 formulation of luxeptinib, a potent, non-covalent oral inhibitor of BTK and FLT3, in the ongoing Phase 1a/b clinical trial in patients with relapsed or refractory (r/r) ac

  • GlobeNewswire

    Aptose Clinical Data to be Presented at the 2022 ASH Annual Meeting

    Data for Tuspetinib (HM43239) and Luxeptinib Accepted for Poster PresentationSAN DIEGO and TORONTO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that clinical data for tuspetinib (formerly HM43239), a myeloid kinome inhibitor, and luxeptinib, a dual lymphoid and myeloid inhibitor, have been accepted for poster pres

  • GlobeNewswire

    Aptose Reports Results for the Third Quarter 2022

    ─ Tuspetinib (HM43239) Dose Escalation and Exploration Phase 1/2 Trial in r/r AML Complete; Continued Superior Safety Profile and Clinical Responses Including Complete Remissions as Single Agent Across Three Dose Levels ─ ─ Recruitment Open for Tuspetinib Dose Expansion Trial with Enriched Populations ─ ─ Continuous Dosing of G3 Formulation of Luxeptinib to Begin Soon ─ ─ Conference Call and Webcast at 5:00 pm ET Today ─ SAN DIEGO and TORONTO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences